Is Wall Street Bullish or Bearish on Gilead Sciences Stock?

Core Viewpoint - Gilead Sciences, Inc. is a leading biopharmaceutical company with a market cap of $147.4 billion, focusing on treatments for serious infectious diseases and oncology, showing strong stock performance relative to the broader market and sector peers [1][4]. Performance Summary - Gilead's stock has increased by 34.2% over the past year, outperforming the S&P 500 Index, which rose by 17.4% during the same period [2]. - Year-to-date in 2025, Gilead's stock is up 28.2%, again surpassing the S&P 500's 16% increase [2]. - Compared to sector peers, the Invesco Pharmaceuticals ETF has gained 9.8% over the past year and 15.7% year-to-date, still trailing Gilead's performance [3]. Financial Performance - In Q3 2025, Gilead reported total revenues of $7.8 billion, a 3% increase from the previous year, with product sales at $7.3 billion, down 2% year-over-year [5]. - Excluding COVID-19 antiviral sales, product sales rose by 4% to $7.1 billion, driven by strong performance in HIV treatments and liver-disease therapies [5]. - The company reported a non-GAAP EPS of $2.47, up from $2.02 a year ago, indicating a strong profit beat [5]. Future Projections - For FY2025, Gilead's management projects product sales between $28.4 billion and $28.7 billion, excluding Veklury, with expected sales between $27.4 billion and $27.7 billion [6]. - Analysts anticipate Gilead's EPS to grow by 74.7% to $8.07 for the current fiscal year ending in December [6]. - The company's earnings surprise history shows mixed results, beating consensus estimates in three of the last four quarters [7].